Abstract:Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that the 'Control' and 'NC' data panels shown in Fig. 2E on p. 981, showing the results of Transwell invasion assay experiments, appeared to contain overlapping sections of data, such that they were potentially derived from the same original source where these panels were intended to show the results from differently performed experiments. After having asked the authors to provide an explanation of these data, they realized that this figure had been inadvertently assembled incorrectly. A revised version of Fig. 2, containing replacement data for the experiments portrayed in Fig. 2E, is shown on the next page. Note that these errors did not adversely affect either the results or the overall conclusions reported in this study. All the authors agree with the publication of this corrigendum, and are grateful to the Editor of Molecular Medicine Reports for allowing them the opportunity to publish this. They also wish to apologize to the readership of the Journal for any inconvenience caused. [Molecular Medicine Reports 20: 977‐984, 2019; DOI: 10.3892/mmr.2019.10332]

Author Correction: Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells

Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells

Corrigendum: Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer

Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts: Erratum

Correction To: Targeted Therapy for Cisplatin‐resistant Lung Cancer Via Aptamer‐guided Nano‐zinc Carriers Containing USP14 Sirna

Correction to: Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p

Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

Author Correction: Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling

Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer

Correction to: Exosomes derived from gemcitabine resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p

Publisher Correction: ‘TRAIL-based gene delivery and therapeutic strategies’ and ‘Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy’

Author Correction: A Next-Generation Tumor-Targeting IL-2 Preferentially Promotes Tumor-Infiltrating CD8+ T-cell Response and Effective Tumor Control

Correction: Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications

Author Correction: Quiescence and Attenuated DNA Damage Response Promote Survival of Esophageal Cancer Stem Cells

Correction: the Lipogenic LXR-SREBF1 Signaling Pathway Controls Cancer Cell DNA Repair and Apoptosis and is a Vulnerable Point of Malignant Tumors for Cancer Therapy.

Publisher Correction: A DNA nanodevice-based vaccine for cancer immunotherapy

Author Correction: Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA

Author Correction: PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness

[Corrigendum] Effect of STC2 gene silencing on colorectal cancer cells

Correction: CSN6–TRIM21 axis instigates cancer stemness during tumorigenesis

Correction: Transdifferentiation of Tumor Infiltrating Innate Lymphoid Cells During Progression of Colorectal Cancer